Indian pharmaceutical giant Lupin Limited has announced the launch of its Ipratropium Bromide Nasal Solution (Nasal Spray) in the U.S. market, expanding its presence in the respiratory care segment. The nasal spray will be available in two strengths — 0.03% and 0.06% — and is a generic equivalent of Boehringer Ingelheim’s Atrovent® Nasal Spray.

The 0.03% formulation of the Ipratropium Bromide Nasal Spray is approved for providing symptomatic relief from rhinorrhea (runny nose) caused by allergic and nonallergic perennial rhinitis in adults and children aged six years and above. The 0.06% version is indicated for rhinorrhea associated with the common cold or seasonal allergic rhinitis in individuals aged five years and older.

According to data from IQVIA MAT (Moving Annual Total) as of May 2025, the reference listed drug (RLD) Atrovent® Nasal Spray recorded estimated annual sales of approximately USD 63 million in the United States. With this launch, Lupin aims to capture a share of this market by offering a more affordable, bioequivalent option.

The launch marks another step in Lupin’s strategy to strengthen its respiratory portfolio in key global markets, particularly the United States.